Current Neuro-Oncology

Volume 24 Number 17
15 september 2022

Home > Publications > Current Neuro-Oncology > Volume 24, Year 2022 > Number 17, 15 September

Czech C, Chen A, Morgan KP, Zamora C, El-Refai S, Poynter N, Khagi S.
Response to Selpercatinib in a Patient With Recurrent Glioblastoma and RET Amplification.
J Natl Compr Canc Netw. 2022 Sep;20(9):966-97∟. doi: 10.6004/jnccn.2022.7030∟. PMID: 36075388∟. Case report. ˍ

Huang J, Chan SC, Lok V, Zhang L, Lin X, Lucero-Prisno DE, Xu W, Zheng ZJ, Elcarte E, Withers M, Wong MCS; NCD Global Health Research Group, Association of Pacific Rim Universities (APRU).
Disease Burden, Risk Factors, and Trends of Primary Central Nervous System (CNS) Cancer: a global study of registries data.
Neuro Oncol. 2022 Sep 1, 2022:noac213∟. doi: 10.1093/neuonc/noac213∟. PMID: 36048182∟. Observational study˰ ˍ

Iannó MF, Biassoni V, Schiavello E, Carenzo A, Boschetti L, Gandola L, Diletto B, Marchesi E, Vegetti C, Molla A, Kramm CM, van Vuurden DG, Gasparini P, Gianno F, Giangaspero F, Modena P, Bison B, Anichini A, Vennarini S, Pignoli E, Massimino M, De Cecco L.
A microRNA Prognostic Signature in Patients with Diffuse Intrinsic Pontine Gliomas through Non-Invasive Liquid Biopsy.
Cancers (Basel). 2022 Sep 2;14(17):4307∟. doi: 10.3390/cancers14174307∟. PMID: 36077842∟. Laboratory investigation. ˍ

Shidoh S, Savjani RR, Cho NS, Ullman HE, Hagiwara A, Raymond C, Lai A, Nghiemphu PL, Liau LM, Pope WB, Cloughesy TF, Kaprealian TB, Salamon N, Ellingson BM.
Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation.
J Neurooncol. 2022 Sep 2∟. doi: 10.1007/s11060-022-04123-3∟. PMID: 36053452∟. Observational study. ˍ

Truckenmueller P, Graef J, Scheel M, Vajkoczy P, Capper D, Kaul D, Furth C, Amthauer H, Brenner W, Onken JS.
[⁶⁸Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [¹⁷⁷Lu]Lu-PSMA therapy in relapsing high-grade glioma.
Front Oncol. 2022 Sep 2;12:980058∟. doi: 10.3389/fonc.2022.980058∟. PMID: 36119502∟. Observational study. ˍ

Deacu M, Docu Axelerad A, Popescu S, Topliceanu TS, Aschie M, Bosoteanu M, Cozaru GC, Cretu AM, Voda RI, Orasanu CI.
Aggressiveness of Grade 4 Gliomas of Adults.
Clin Pract. 2022 Sep 3;12(5):701-713∟. doi: 10.3390/clinpract12050073∟. PMID: 36136867∟. Observational study. ˍ

Conte B, Rich BJ, Gultekin SH, Azzam G, Del Pilar Guillermo Prieto Eibl M.
A Case of Glioblastoma, Isocitrate Dehydrogenase Wild Type, With Widely Disseminated Osseous Metastasis.
Cureus. 2022 Sep 5;14(9):e28803∟. doi: 10.7759/cureus.28803∟. PMID: 36225424∟. Case report. ˍ

*

Morelli M, Lessi F, Barachini S, Liotti R, Montemurro N, Perrini P, Santonocito OS, Gambacciani C, Snuderl M, Pieri F, Aquila F, Farnesi A, Naccarato AG, Viacava P, Cardarelli F, Ferri G, Mulholland P, Ottaviani D, Paiar F, Liberti G, Pasqualetti F, Menicagli M, Aretini P, Signore G, Franceschi S, Mazzanti CM.
Metabolic-imaging of human glioblastoma live tumors: A new precision-medicine approach to predict tumor treatment response early.
Front Oncol. 2022 Sep 5;12:969812∟. doi: 10.3389/fonc.2022.969812∟. PMID: 36132155∟. Observational study. ˍ

Snyder MH, Yu-Der Wang A, Ampie L, Sarathy D, Chatrath A, Asthagiri AR, Shaffrey CI, Smith JS, Shaffrey ME, Yen CP, Buchholz AL, Syed HR, Kryzanski J, Wu JK, Heilman CB.
Primary Spinal Cord Astrocytomas: Two Center Clinical Experience of Low- and High-grade Lesions.
World Neurosurg. 2022 Sep 5, 2022:S1878-8750(22)01239-6∟. doi: 10.1016/j.wneu.2022.08.130∟. PMID: 36064118∟. Observational study˰ ˍ

Zhang M, Gao L, Liu X, Dong F, Su Q, Zhang Y, Li F, Wang H, Han P.
Low-Dose Apatinib Improves the Prognosis of Patients with Recurrent High-Grade Gliomas.
Evid Based Complement Alternat Med. 2022 Sep 5;2022:3181133∟. doi: 10.1155/2022/3181133∟. PMID: 36106030∟. Observational study. ˍ

Anttonen J, Remes T, Arikoski P, Lähteenmäki P, Arola M, Harila-Saari A, Lönnqvist T, Pokka T, Riikonen P, Sirkiä K, Rantala H, Ojaniemi M.
Pre- and postdiagnosis growth failure, adult short stature, and untreated growth hormone deficiency in radiotherapy-treated long-term survivors of childhood brain tumor.
PLoS One. 2022 Sep 6;17(9):e0274274∟. doi: 10.1371/journal.pone.0274274∟. PMID: 36067205∟. Observational study. ˍ

Del Baldo G, Carai A, Abbas R, Cacchione A, Vinci M, Di Ruscio V, Colafati GS, Rossi S, Diomedi Camassei F, Maestro N, Temelso S, Pericoli G, De Billy E, Giovannoni I, Carboni A, Rinelli M, Agolini E, Mackay A, Jones C, Chiesa S, Balducci M, Locatelli F, Mastronuzzi A.
Targeted therapy for pediatric diffuse intrinsic pontine glioma: a single-center experience.
Ther Adv Med Oncol. 2022 Sep 6;14:17588359221113693∟. doi: 10.1177/17588359221113693∟. PMID: 36090803∟. Observational study. ˍ

Ostrom QT, Price M, Ryan K, Edelson J, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS.
CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.
Neuro Oncol. 2022 Sep 6;24(Suppl_3):iii1-iii38∟. doi: 10.1093/neuonc/noac161∟. PMID: 36066969∟. Observational study. ˍ

*

Kumaria A, Noah A, Kirkman MA.
Does covid-19 impair endogenous neurogenesis?
J Clin Neurosci. 2022 Sep 7;105:79-85∟. doi: 10.1016/j.jocn.2022.09.006∟. PMID: 36113246∟. Laboratory investigation. ˍ

Rades D, Witteler J, Trillenberg P, Olbrich D, Schild SE, Tvilsted S, Kjaer TW.
Increasing Seizure Activity During Radiation Treatment for High-grade Gliomas - Final Results of a Prospective Interventional Study.
In Vivo. 2022 Sep 7;36(5):2308-2313∟. doi: 10.21873/invivo.12961∟. PMID: 36099095∟. Interventional study. ˍ

Horikawa M, Koizumi S, Oishi T, Yamamoto T, Ikeno M, Ito M, Yamasaki T, Amano S, Sameshima T, Mitani Y, Otani Y, Yan Y, Suzuki T, Namba H, Kurozumi K.
Potent bystander effect and tumor tropism in suicide gene therapy using stem cells from human exfoliated deciduous teeth.
Cancer Gene Ther. 2022 Sep 8∟. doi: 10.1038/s41417-022-00527-5∟. PMID: 36076062∟. Laboratory investigation˰ ˍ

Huang X, Hansen J, Lee PC, Wu CK, Federman N, Arah OA, Li CY, Olsen J, Ritz B, Heck JE.
Maternal diabetes and childhood cancer risks in offspring: two population-based studies.
Br J Cancer. 2022 Sep 10∟. doi: 10.1038/s41416-022-01961-w∟. PMID: 36088507∟. Observational study. ˍ

Torre M, Wen PY, Iorgulescu JB.
The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients.
Neurooncol Pract. 2022 Sep 10, 2023;10(2):126-131∟. doi: 10.1093/nop/npac070∟. PMID: 36970171∟. Observational study. ˍ

Woo PYM, Yau S, Lam TC, Pu JKS, Li LF, Lui LCY, Chan DTM, Loong HHF, Lee MWY, Yeung R, Kwok CCH, Au SK, Tan TC, Kan ANC, Chan TKT, Mak CHK, Mak HKF, Ho JMK, Cheung KM, Tse TPK, Lau SSN, Chow JSW, El-Helali A, Ng HK, Poon WS.
Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: a Hong Kong population-level analysis over a 14-year period.
Neurooncol Pract. 2022 Sep 10, 2023;10(1):50-61∟. doi: 10.1093/nop/npac069∟. PMID: 36659973∟. Observational study. ˍ

Damodharan S, Helgager J, Puccetti D.
Indolent presentation of a diffuse midline glioma, H3 K27-altered.
Childs Nerv Syst. 2022 Sep 12∟. doi: 10.1007/s00381-022-05668-4∟. PMID: 36094605∟. Case report˰ ˍ

Gardner SL, Tarapore RS, Allen J, McGovern SL, Zaky W, Odia Y, Daghistani D, Diaz Z, Hall MD, Khatib Z, Koschmann C, Cantor E, Kurokawa R, MacDonald TJ, Aguilera D, Vitanza NA, Mueller S, Kline C, Lu G, Allen JE, Khatua S.
Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy.
Neurooncol Adv. 2022 Sep 13;4(1):vdac143∟. doi: 10.1093/noajnl/vdac143∟. PMID: 36382108∟. Interventional study. ˍ

Sekely A, Bernstein LJ, Campbell KL, Mason WP, Laperriere N, Kalidindi N, Or R, Ramos R, Climans SA, Pond GR, Ann Millar B, Shultz D, Tsang DS, Zadeh G, Edelstein K.
Neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in patients with newly diagnosed glioblastoma.
Neurooncol Pract. 2022 Sep 13, 2023;10(1):89-96∟. doi: 10.1093/nop/npac068∟. PMID: 36659968∟. Observational study˰ ˍ

Kong BY, Sim HW, Barnes EH, Nowak AK, Hovey EJ, Jeffree R, Harrup R, Parkinson J, Gan HK, Pinkham MB, Yip S, Hall M, Tu E, Carter C, Koh ES, Lwin Z, Dowling A, Simes JS, Gedye C.
Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma.
BMJ Open. 2022 Sep 14;12(9):e058107∟. doi: 10.1136/bmjopen-2021-058107∟. PMID: 36104135∟. Protocol. ˍ

Ballo MT, Qualls KW, Michael LM, Sorenson JM, Baughman B, Karri-Wellikoff S, Pandey M.
Determinants of tumor treating field usage in patients with primary glioblastoma: A single institutional experience.
Neurooncol Adv. 2022 Sep 15;4(1):vdac150∟. doi: 10.1093/noajnl/vdac150∟. PMID: 36249289∟. Observational study. ˍ

Nuijts MA, Stegeman I, van Seeters T, Borst MD, Bennebroek CAM, Buis DR, Naus NC, Porro GL, van Egmond-Ebbeling MB, Voskuil-Kerkhof ESM, Pott JR, Franke NE, de Vos-Kerkhof E, Hoving EW, Schouten-van Meeteren AYN, Imhof SM.
Ophthalmological Findings in Youths With a Newly Diagnosed Brain Tumor.
JAMA Ophthalmol. 2022 Sep 15;140(10):982-993∟. doi: 10.1001/jamaophthalmol.2022.3628∟. PMID: 36107418∟. Interventional study˰ ˍ